{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T20:19:50Z","timestamp":1782937190961,"version":"3.54.5"},"reference-count":46,"publisher":"American Society of Hematology","issue":"15","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4,9]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Core-binding factor acute myeloid leukemia (CBF-AML) is associated with KIT mutations and deregulated expression of KIT. We report results from the randomized, open-label, phase 3 trial of intensive chemotherapy with or without the multikinase inhibitor dasatinib in adult patients with CBF-AML. Patients received \u201c3+7\u201d induction therapy, followed by 4 cycles of high-dose cytarabine; in the investigational arm, patients received dasatinib 100 mg daily on days 8 to 21 in induction, and on days 6 to 28 in consolidation cycles, followed by 12-month single-agent dasatinib 100 mg daily. Primary end point was event-free survival (EFS). Secondary end points included overall survival, relapse-free survival, and cumulative incidence of relapse. A total of 202 patients were randomly assigned to the standard arm (n = 102) and to the dasatinib arm (n = 100). Median age was 49 years (range, 18-77); 94 patients had t(8;21), 108 had inv(16)\/t(16;16); and 58 (28.7%) patients had a KIT comutation. There was no statistically significant difference in EFS (hazard ratio, 0.92; 95% confidence interval, 0.63-1.33; P = .66) or secondary end points between treatment arms. There was also no significant difference in EFS in subgroup analyses according to age, CBF-AML type, and KIT mutation status. The incidence of serious adverse events was higher in the investigational arm (64%) than in the standard arm (36%). In patients with CBF-AML, the addition of dasatinib to intensive chemotherapy failed to improve survival outcomes. The addition of dasatinib was associated with an increase in toxicity. This trial was registered at www.ClinicalTrials.gov as NCT02013648.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025030722","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T19:42:32Z","timestamp":1767642152000},"page":"1735-1748","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":4,"title":["A phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia"],"prefix":"10.1182","volume":"147","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2116-5536","authenticated-orcid":false,"given":"Hartmut","family":"D\u00f6hner","sequence":"first","affiliation":[{"name":"1Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Sp\u00e4th","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maral","family":"Saadati","sequence":"additional","affiliation":[{"name":"2Division of Biostatistics, German Cancer Research Center, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Fiedler","sequence":"additional","affiliation":[{"name":"3Hubertus Wald University Cancer Center, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6276-8002","authenticated-orcid":false,"given":"Katharina","family":"G\u00f6tze","sequence":"additional","affiliation":[{"name":"4Department of Medicine III, Hematology and Medical Oncology, Technical University of Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Koller","sequence":"additional","affiliation":[{"name":"5Department of Internal Medicine III, Hanuschkrankenhaus Wien, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Westermann","sequence":"additional","affiliation":[{"name":"6Department of Hematology, Oncology, and Cancer Immunology, Charit\u00e9-Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, and Berlin Institute of Health, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wichard","family":"Vogel","sequence":"additional","affiliation":[{"name":"7Department of Hematology and Oncology, Eberhard-Karls University, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Heuser","sequence":"additional","affiliation":[{"name":"8Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany"},{"name":"9Department of Hematology, Oncology and Hemostaseology, University Hospital Halle, Halle (Saale), Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"L\u00fcbbert","sequence":"additional","affiliation":[{"name":"10Department of Medicine I, Medical Center\u2013University of Freiburg, Faculty of Medicine, University of Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Joachim","family":"Tischler","sequence":"additional","affiliation":[{"name":"11Department of Hematology and Oncology, University Hospital of Minden, Minden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Germing","sequence":"additional","affiliation":[{"name":"12Department of Hematology, Oncology, and Clinical Immunology, Heinrich Heine University D\u00fcsseldorf, D\u00fcsseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9489-7282","authenticated-orcid":false,"given":"Lino L.","family":"Teichmann","sequence":"additional","affiliation":[{"name":"13Department of Medicine III, University Hospital Bonn, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3658-0284","authenticated-orcid":false,"given":"Lars","family":"Fransecky","sequence":"additional","affiliation":[{"name":"14Department of Internal Medicine II, University Hospital Schleswig Holstein, Campus Kiel, Kiel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3112-9857","authenticated-orcid":false,"given":"Albert","family":"W\u00f6lfler","sequence":"additional","affiliation":[{"name":"15Division of Hematology, Department of Internal Medicine, Medical University of Graz, Graz, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Nachbaur","sequence":"additional","affiliation":[{"name":"16Internal Medicine V, Hematology and Oncology, Medical University of Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Hertenstein","sequence":"additional","affiliation":[{"name":"17Department of Hematology and Oncology, Klinikum Bremen-Mitte, Bremen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2744-5491","authenticated-orcid":false,"given":"Roland","family":"Schroers","sequence":"additional","affiliation":[{"name":"18Medical Clinic II-Hematology and Oncology, Ruhr-University Bochum, Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7999-4359","authenticated-orcid":false,"given":"Uwe","family":"Martens","sequence":"additional","affiliation":[{"name":"19Department of Hematology and Oncology, SLK-Clinics Heilbronn GmbH, Heilbronn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"von Harsdorf","sequence":"additional","affiliation":[{"name":"20Klinik f\u00fcr H\u00e4matologie, Onkologie & Stammzelltransplantation, Evangelische Kliniken Essen-Mitte, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3991-5721","authenticated-orcid":false,"given":"Markus","family":"Radsak","sequence":"additional","affiliation":[{"name":"21Department of Hematology, Medical Oncology and Pneumology, University Medical Center, Johannes Gutenberg-University Mainz, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"Aschauer","sequence":"additional","affiliation":[{"name":"22Internal Medicine I, Medical Oncology, Hematology and Gastroenterology, Barmherzige Schwestern Hospital, Linz, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Wei\u00dfhaar","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Corbacioglu","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anika","family":"Schrade","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verena I.","family":"Gaidzik","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicitas","family":"Thol","sequence":"additional","affiliation":[{"name":"8Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Paschka","sequence":"additional","affiliation":[{"name":"23Klinikum der Stadt Ludwigshafen am Rhein, Medizinische Klinik A, Ludwigshafen am Rhein, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Bullinger","sequence":"additional","affiliation":[{"name":"6Department of Hematology, Oncology, and Cancer Immunology, Charit\u00e9-Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, and Berlin Institute of Health, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7238-6956","authenticated-orcid":false,"given":"Axel","family":"Benner","sequence":"additional","affiliation":[{"name":"2Division of Biostatistics, German Cancer Research Center, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstanze","family":"D\u00f6hner","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3510-4304","authenticated-orcid":false,"given":"Arnold","family":"Ganser","sequence":"additional","affiliation":[{"name":"8Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"11","key":"2026040911265127400_bib1","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of myeloid neoplasms and acute leukemia: integrating morphological, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"7","key":"2026040911265127400_bib2","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"12","key":"2026040911265127400_bib3","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1038\/ng.3709","article-title":"The genomic landscape of core-binding factor acute myeloid leukemias","volume":"48","author":"Faber","year":"2016","journal-title":"Nat Genet"},{"issue":"20","key":"2026040911265127400_bib4","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1182\/blood-2015-12-688705","article-title":"Comprehensive mutational profiling of core binding factor acute myeloid leukemia","volume":"127","author":"Duployez","year":"2016","journal-title":"Blood"},{"issue":"10","key":"2026040911265127400_bib5","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1182\/blood-2018-05-852822","article-title":"Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients","volume":"133","author":"Christen","year":"2019","journal-title":"Blood"},{"issue":"24","key":"2026040911265127400_bib6","doi-asserted-by":"crossref","first-page":"6342","DOI":"10.1182\/bloodadvances.2020002673","article-title":"Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication","volume":"4","author":"Jahn","year":"2020  22","journal-title":"Blood Adv"},{"issue":"12","key":"2026040911265127400_bib7","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"2026040911265127400_bib8","doi-asserted-by":"crossref","first-page":"3904","DOI":"10.1200\/JCO.2006.06.9500","article-title":"Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): A Cancer and Leukmia Group B Study","volume":"24","author":"Paschka","year":"2006","journal-title":"J Clin Oncol"},{"key":"2026040911265127400_bib9","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1182\/asheducation-2013.1.209","article-title":"Core-binding factor acute myeloid leukemia: can we improve on HiDAC consolidation?","volume":"2013","author":"Paschka","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"9","key":"2026040911265127400_bib10","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1038\/leu.2013.186","article-title":"The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor leukemia","volume":"27","author":"Allen","year":"2013","journal-title":"Leukemia"},{"issue":"2","key":"2026040911265127400_bib11","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s00277-012-1580-5","article-title":"KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1\/RUNX1T1 rearrangement","volume":"92","author":"Kim","year":"2013","journal-title":"Ann Hematol"},{"issue":"1","key":"2026040911265127400_bib12","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1182\/bloodadvances.2019000709","article-title":"Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11","volume":"4","author":"Ishikawa","year":"2020","journal-title":"Blood Adv"},{"issue":"7","key":"2026040911265127400_bib13","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/onc.2010.494","article-title":"Tumor-intrinsic and -extrinsic roles of c-Kit: mast cells as the primary off-target of tyrosine kinase inhibitors","volume":"30","author":"Pittoni","year":"2011","journal-title":"Oncogene"},{"issue":"5","key":"2026040911265127400_bib14","doi-asserted-by":"crossref","first-page":"435","DOI":"10.7150\/ijbs.6087","article-title":"The C-kit receptor-mediated signal transduction and tumor-related diseases","volume":"9","author":"Liang","year":"2013","journal-title":"Int J Biol Sci"},{"issue":"16","key":"2026040911265127400_bib15","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1056\/NEJMoa031046","article-title":"Use of gene expression profiling to identify prognostic subclasses in adult acute myeloid leukemia","volume":"350","author":"Bullinger","year":"2004","journal-title":"N Engl J Med"},{"issue":"16","key":"2026040911265127400_bib16","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1056\/NEJMoa040465","article-title":"Prognostically useful gene-expression profiles in acute myeloid leukemia","volume":"350","author":"Valk","year":"2004  15","journal-title":"N Engl J Med"},{"issue":"4","key":"2026040911265127400_bib17","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1073\/pnas.0408831102","article-title":"AML1-ETO and C-KIT mutation\/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec","volume":"102","author":"Wang","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"2026040911265127400_bib18","doi-asserted-by":"crossref","first-page":"e0124241","DOI":"10.1371\/journal.pone.0124241","article-title":"High expression of c-kit mRNA predicts unfavorable outcome in adult patients with t(8;21) acute myeloid leukemia","volume":"10","author":"Gao","year":"2015","journal-title":"PLoS One"},{"issue":"12","key":"2026040911265127400_bib19","doi-asserted-by":"crossref","first-page":"3958","DOI":"10.1182\/blood-2005-02-0583","article-title":"Extracellular KIT receptor mutants, commonly found in core binding factor AML, are constitutively active and respond to imatinib mesylate","volume":"106","author":"Cammenga","year":"2005","journal-title":"Blood"},{"issue":"2","key":"2026040911265127400_bib20","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1182\/blood-2004-12-4617","article-title":"Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412","volume":"106","author":"Growney","year":"2005","journal-title":"Blood"},{"issue":"1","key":"2026040911265127400_bib21","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1158\/0008-5472.CAN-05-2050","article-title":"Dasatinib (BMS-354825), a dual SRC\/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies","volume":"66","author":"Schittenhelm","year":"2006","journal-title":"Cancer Res"},{"issue":"4","key":"2026040911265127400_bib22","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1158\/1078-0432.CCR-09-2416","article-title":"Dasatinib inhibits the growth of molecularly heterogeneous myeloid leukemias","volume":"16","author":"Guerrouahen","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2026040911265127400_bib23","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1476-4598-12-19","article-title":"Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms","volume":"12","author":"Kampa-Schittenhelm","year":"2013","journal-title":"Mol Cancer"},{"issue":"6","key":"2026040911265127400_bib24","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1073\/pnas.1019625108","article-title":"C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice","volume":"108","author":"Wang","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"2026040911265127400_bib25","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1182\/blood-2012-11-466425","article-title":"The Src and c-Kit kinase inhibitor dasatinib enhances p53-mediated targeting of human acute myeloid leukemia stem cells by chemotherapeutic agents","volume":"122","author":"Dos Santos","year":"2013","journal-title":"Blood"},{"issue":"7","key":"2026040911265127400_bib26","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1038\/s41375-018-0129-6","article-title":"Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial","volume":"32","author":"Paschka","year":"2018","journal-title":"Leukemia"},{"issue":"4","key":"2026040911265127400_bib27","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1182\/bloodadvances.2019000492","article-title":"Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801","volume":"4","author":"Marcucci","year":"2020","journal-title":"Blood Adv"},{"issue":"12","key":"2026040911265127400_bib28","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1007\/s00277-017-3150-3","article-title":"German-Austrian AML Study Group (AMLSG). Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO)","volume":"96","author":"Nagel","year":"2017","journal-title":"Ann Hematol"},{"issue":"1","key":"2026040911265127400_bib29","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1182\/blood-2012-05-431486","article-title":"Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): A study of the German-Austrian AML Study Group (AMLSG)","volume":"121","author":"Paschka","year":"2013","journal-title":"Blood"},{"issue":"5","key":"2026040911265127400_bib30","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"issue":"23","key":"2026040911265127400_bib31","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1200\/JCO.2010.28.6468","article-title":"Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia","volume":"28","author":"Corbacioglu","year":"2010","journal-title":"J Clin Oncol"},{"issue":"19","key":"2026040911265127400_bib32","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1182\/blood.2019001425","article-title":"Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group","volume":"134","author":"R\u00fccker","year":"2019","journal-title":"Blood"},{"issue":"4","key":"2026040911265127400_bib33","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1177\/0962280214521348","article-title":"Alzheimer's Disease Neuroimaging Initiative. Multiple imputation of covariates by fully conditional specification: accommodating the substantive model","volume":"24","author":"Bartlett","year":"2015","journal-title":"Stat Methods Med Res"},{"key":"2026040911265127400_bib34","article-title":"smcfcs: Multiple imputation of covariates by substantive model compatible fully conditional specification","author":"Bartlett","year":"2025","journal-title":"R Package Version 1.9.2"},{"key":"2026040911265127400_bib35","author":"Rubin","year":"2004"},{"issue":"26","key":"2026040911265127400_bib36","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"issue":"9","key":"2026040911265127400_bib37","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S1470-2045(14)70281-5","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials","volume":"15","author":"Hills","year":"2014","journal-title":"Lancet Oncol"},{"issue":"11","key":"2026040911265127400_bib38","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1002\/ajh.26700","article-title":"Retrospective comparison of survival and responses to fludarabine, cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderson experience in 174 patients","volume":"97","author":"Borthakur","year":"2022","journal-title":"Am J Hematol"},{"issue":"2","key":"2026040911265127400_bib39","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/ajh.27547","article-title":"Efficacy of midostaurin combined with intensive chemotherapy in core binding factor leukemia: a phase ii clinical trial","volume":"100","author":"Cairoli","year":"2025","journal-title":"Am J Hematol"},{"issue":"9","key":"2026040911265127400_bib40","first-page":"2520","article-title":"Midostaurin in addition to intensive chemotherapy in acute myeloid leukemia with t(8;21) and KIT and\/or FLT3- ITD mutations: results of the SAL MIDOKIT trial","volume":"108","author":"Ruhnke","year":"2023","journal-title":"Haematologica"},{"issue":"4","key":"2026040911265127400_bib41","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/jha2.981","article-title":"Real-world outcomes of intensive induction approaches in core binding factor acute myeloid leukemia","volume":"5","author":"Rojek","year":"2024","journal-title":"EJHaem"},{"key":"2026040911265127400_bib42","author":"Sprycel","year":"2010"},{"issue":"6","key":"2026040911265127400_bib43","doi-asserted-by":"crossref","first-page":"e66915","DOI":"10.1371\/journal.pone.0066915","article-title":"MEK\/ERK dependent activation of STAT1 mediates dasatinib-induced differentiation of acute myeloid leukemia","volume":"8","author":"Fang","year":"2013","journal-title":"PLoS One"},{"issue":"10","key":"2026040911265127400_bib44","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1038\/leu.2010.151","article-title":"Robust in vivo differentiation of t(8;21)-positive acute myeloid leukemia blasts to neutrophilic granulocytes induced by treatment with dasatinib","volume":"24","author":"Chevalier","year":"2010","journal-title":"Leukemia"},{"issue":"14","key":"2026040911265127400_bib45","doi-asserted-by":"crossref","first-page":"11876","DOI":"10.18632\/oncotarget.24376","article-title":"Dasatinib overrides the differentiation blockage in a patient with mutant-KIT D816V positive CBF\u03b2-MYH11 leukemia","volume":"9","author":"Kampa-Schittenhelm","year":"2018","journal-title":"Oncotarget"},{"issue":"1","key":"2026040911265127400_bib46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clml.2024.06.005","article-title":"SOHO state of the art update and next questions: current and emerging therapies for systemic mastocytosis","volume":"25","author":"Chifotides","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/15\/1735\/2512070\/blood_bld-2025-030722-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/15\/1735\/2512070\/blood_bld-2025-030722-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T15:27:06Z","timestamp":1775748426000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/147\/15\/1735\/565857\/A-phase-3-study-of-intensive-chemotherapy-with-or"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,9]]},"references-count":46,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2026,4,9]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025030722","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4,9]]},"published":{"date-parts":[[2026,4,9]]}}}